CSF metabolic and proteomic profiles in patients prodromal for psychosis.
about
Neuropeptides in depression: role of VGFThe role of the vgf gene and VGF-derived peptides in nutrition and metabolismRevisiting the Basic Symptom Concept: Toward Translating Risk Symptoms for Psychosis into Neurobiological TargetsA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesSystematic NMR analysis of stable isotope labeled metabolite mixtures in plant and animal systems: coarse grained views of metabolic pathwaysResearch in people with psychosis risk syndrome: a review of the current evidence and future directionsMetabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions.Molecular characterization and quantification using state of the art solid-state adiabatic TOBSY NMR in burn trauma.Profiles of VGF Peptides in the Rat Brain and Their Modulations after Phencyclidine Treatment.Inflammatory molecular signature associated with infectious agents in psychosis.Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples.Behavioural and molecular endophenotypes in psychotic disorders reveal heritable abnormalities in glutamatergic neurotransmission.Potential metabolite markers of schizophrenia.Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: A preliminary study.Increased lactate levels and reduced pH in postmortem brains of schizophrenics: medication confoundsThe extended granin family: structure, function, and biomedical implicationsThe proteome of schizophrenia.Consanguinity associated with increased risk for bipolar I disorder in EgyptSchizophrenia genomics and proteomics: are we any closer to biomarker discovery?Cerebrospinal fluid: identification of diagnostic markers for schizophrenia.Psychiatric research: psychoproteomics, degradomics and systems biology.The audacity of proteomics: a chance to overcome current challenges in schizophrenia research.2D DIGE of the cerebrospinal fluid proteome in neurological diseases.Proteomic research in psychiatry.Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders.Metabonomic studies of schizophrenia and psychotropic medications: focus on alterations in CNS energy homeostasis.Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?Proteomic approaches to unravel the complexity of schizophrenia.Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression.Genealogy of instruments for prodrome evaluation of psychosis.Carbonyl stress and schizophrenia.Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms.Transcriptional regulation of neurodevelopmental and metabolic pathways by NPAS3.Protective effects of haloperidol and clozapine on energy-deprived OLN-93 oligodendrocytes.Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls.Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder.Proteomic analysis of cerebrospinal fluid from obese women with idiopathic intracranial hypertension: a new approach for identifying new candidates in the pathogenesis of obesity.Endocannabinoids and Schizophrenia.Early Detection and Treatment of Psychosis: The Bern Child and Adolescent Psychiatric Perspective
P2860
Q24647788-ADB4AEF1-7454-4184-B852-B367D817F5BDQ24657048-8EAAF3E8-EAFC-4097-9258-E3939A10BF64Q26767499-42B59274-FD76-4159-8A80-8F39F8F378D9Q26786354-BD5C8B70-F817-4D05-A027-B8F4D26EC78FQ28474093-83AEFA3F-CD68-4580-A38B-EB43EB33C73AQ30475598-17C5C56A-4502-411D-BC88-DDAE1DF74AC2Q30885784-65D38659-47E5-4EF0-8FF8-A5BE27DA4F6DQ33514649-F6243892-E485-4DC6-953A-A859AEDCF48CQ33753194-0692E23D-2A5A-480F-AF31-78B42D2E4E2DQ34048637-B9BBB61D-4B4A-4582-A3C1-E51F9EA76605Q34194779-098152AB-43FF-46FB-91B2-FB39EB106D0FQ35598785-56380063-37DB-4E1F-B7CA-B29ADC092FE3Q36479055-0F90A03D-38BC-4388-B62E-E7173A73BBF9Q36526417-3B12E596-7119-486B-8607-1481DFDFFFD8Q36528676-DFAF94AB-7CE7-4AF3-A9A9-A177CFEE8AB6Q36666413-45896BB1-1AA3-444C-99D8-610C12232663Q36848272-C8A77038-E847-4D8F-BB38-B88EEE4895C4Q36997388-CB561E20-C3B6-4C26-AD35-698A806C0B77Q37064920-1A4B7E02-01D0-490A-B91F-F15F6BBA5826Q37118995-090701D7-BBE5-4581-8126-C2B34E1A6771Q37157851-401303C2-C86E-4F2C-BE22-A6B8D91C6EBFQ37636121-C1A4201B-7BCC-4AF4-9767-81D0A36ABCE7Q37685107-7943C828-1FAF-40FF-A9FD-700443834F42Q37689362-5070FF03-2363-4351-8F25-547A0A6E486AQ37691267-B9EF8A0D-C0D2-403A-B1D5-D7DB90DE7BABQ37810163-B1A69BEA-4648-4300-B73A-2C2A78C89848Q37968946-819A72EE-6C60-4648-B6EF-6339AC4CF46CQ37980246-60F72B0C-9C0D-4E97-AA7B-D908B1850976Q37980501-4C45AC68-B29C-4591-AB3A-7CC654AC9E0EQ38101557-264AB000-F644-4EEF-B31B-43C3A3FE9585Q38226316-B939B19E-555F-42BD-BFEE-E80185CE3DC5Q38805367-8B31271E-70AD-4338-8697-93EAF3B615D6Q39516883-2F5F593D-CFB6-4E56-AA3D-1543142F8CBBQ39590683-676FABFD-F75B-4DF9-9042-4000C81A8661Q43072099-5E1A530D-0574-44E6-AA73-548CA89C33B9Q46767416-FB969F2E-50F9-4ED1-B8FD-2FD06D449E51Q48681556-0F339966-A7CB-4684-B825-802B9FBDF1F3Q55452539-9D224C1F-15C8-4450-87D8-A363AF18AF5BQ59050567-47F9D56A-2228-44BB-924F-A2308480E8FB
P2860
CSF metabolic and proteomic profiles in patients prodromal for psychosis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
CSF metabolic and proteomic profiles in patients prodromal for psychosis
@nl
CSF metabolic and proteomic profiles in patients prodromal for psychosis.
@ast
CSF metabolic and proteomic profiles in patients prodromal for psychosis.
@en
type
label
CSF metabolic and proteomic profiles in patients prodromal for psychosis
@nl
CSF metabolic and proteomic profiles in patients prodromal for psychosis.
@ast
CSF metabolic and proteomic profiles in patients prodromal for psychosis.
@en
altLabel
CSF metabolic and proteomic profiles in patients prodromal for psychosis
@en
prefLabel
CSF metabolic and proteomic profiles in patients prodromal for psychosis
@nl
CSF metabolic and proteomic profiles in patients prodromal for psychosis.
@ast
CSF metabolic and proteomic profiles in patients prodromal for psychosis.
@en
P2093
P2860
P50
P1433
P1476
CSF metabolic and proteomic profiles in patients prodromal for psychosis.
@en
P2093
Christoph W Gerth
Dagmar Koethe
Daniela Schreiber
Elaine Holmes
F Markus Leweke
Frauke Schultze-Lutter
Jeffrey T-J Huang
Joachim Klosterkötter
Laura Kranaster
Sonja Gross
P2860
P356
10.1371/JOURNAL.PONE.0000756
P407
P577
2007-08-22T00:00:00Z